代谢综合征和肾癌的研究进展

施旭; 冯德超; 李登雄; 魏武然

doi:10.13201/j.issn.1001-1420.2022.09.014

代谢综合征和肾癌的研究进展

- 四川大学华西医院泌尿外科四川大学华西医院泌尿外科研究所(成都，610041)
基金项目:
四川省科技厅重点研发项目(No：2020YFH0099)

详细信息

通讯作者: 魏武然，E-mail：weiwuran@126.com

^Δ审校者

中图分类号: R692

收稿日期: 2021-09-28

刊出日期: 2022-09-06

Research progress of metabolic syndrome and renal cancer

- Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, 610041, China

More Information

Corresponding author: WEI Wuran, E-mail: weiwuran@126.com

Received Date: 28 September 2021

Publish Date: 06 September 2022

摘要

摘要: 代谢综合征(MS)是一组以肥胖、高血压、血脂异常和高血糖为特点的代谢紊乱症候群。越来越多证据表明MS和肾癌的发生发展及预后密切相关，其中肥胖和高血压是已经确定的肾癌的危险因素。本文基于MS及其组分与肾癌发生的风险、侵袭性及预后的关系的研究进展作一综述，从而为肾癌的预防、诊治和预后判断提供参考。
- 代谢综合征 /
- 肾癌 /
- 风险 /
- 侵袭性 /
- 预后
Abstract: Metabolic syndrome (MS) is a group of metabolic disorders characterized by obesity, hypertension, dyslipidemia, and hyperglycemia. More and more evidence show that MS is closely related to the occurrence, development and prognosis of renal cancer, among which obesity and hypertension are established risk factors for renal cancer. This article reviews the research progress of the relationship between MS and renal cancer based on the MS and its components on the risk, aggressiveness and prognosis of renal cancer, so as to provide references for the prevention, diagnosis, treatment and prognosis of renal cancer.
- metabolic syndrome /
- renal cancer /
- risk /
- aggressiveness /
- prognosis

HTML全文

参考文献(75)

[1]	Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease[J]. Diabetes, 1988, 37(12): 1595-1607. doi: 10.2337/diab.37.12.1595
[2]	Aguilar M, Bhuket T, Torres S, et al. Prevalence of the metabolic syndrome in the United States, 2003-2012[J]. JAMA, 2015, 313(19): 1973-1974. doi: 10.1001/jama.2015.4260
[3]	Wang L, Gao P, Zhang M, et al. Prevalence and Ethnic Pattern of Diabetes and Prediabetes in China in 2013[J]. JAMA, 2017, 317(24): 2515-2523. doi: 10.1001/jama.2017.7596
[4]	Caliskan S, Kaba S, Özsoy E, et al. The effect of metabolic syndrome on prostate cancer final pathology[J]. J Cancer Res Ther, 2019, 15(Supplement): S47-S50.
[5]	Colonna SV, Douglas Case L, Lawrence JA. A retrospective review of the metabolic syndrome in women diagnosed with breast cancer and correlation with estrogen receptor[J]. Breast Cancer Res Treat, 2012, 131(1): 325-331. doi: 10.1007/s10549-011-1790-x
[6]	Healy LA, Howard JM, Ryan AM, et al. Metabolic syndrome and leptin are associated with adverse pathological features in male colorectal cancer patients[J]. Colorectal Dis, 2012, 14(2): 157-165. doi: 10.1111/j.1463-1318.2011.02562.x
[7]	Healy LA, Ryan AM, Carroll P, et al. Metabolic syndrome, central obesity and insulin resistance are associated with adverse pathological features in postmenopausal breast cancer[J]. Clin Oncol(R Coll Radiol), 2010, 22(4): 281-288. doi: 10.1016/j.clon.2010.02.001
[8]	Xiang YZ, Xiong H, Cui ZL, et al. The association between metabolic syndrome and the risk of prostate cancer, high-grade prostate cancer, advanced prostate cancer, prostate cancer-specific mortality and biochemical recurrence[J]. J Exp Clin Cancer Res, 2013, 32: 9. doi: 10.1186/1756-9966-32-9
[9]	Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022[J]. CA Cancer J Clin, 2022, 72(1): 7-33. doi: 10.3322/caac.21708
[10]	Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. doi: 10.3322/caac.21660
[11]	李实, 于广海, 陶晓峰, 等. T₁期局限性肾癌剜除平面浸润情况的病理学分析[J]. 临床泌尿外科杂志, 2022, 37(6): 457-460, 465. https://www.cnki.com.cn/Article/CJFDTOTAL-LCMW202206011.htm
[12]	Alexander MP, Patel TV, Farag YM, et al. Kidney pathological changes in metabolic syndrome: a cross-sectional study[J]. Am J Kidney Dis, 2009, 53(5): 751-759. doi: 10.1053/j.ajkd.2009.01.255
[13]	Zhang Y, Wu T, Xie J, et al. Effects of metabolic syndrome on renal function after radical nephrectomy in patients with renal cell carcinoma[J]. Int Urol Nephrol, 2021, 53(10): 2127-2135. doi: 10.1007/s11255-020-02759-6
[14]	李鑫, 李霓, 温艳, 等. 代谢综合征及其组分与男性肾癌发病关联的前瞻性队列研究[J]. 中华预防医学杂志, 2020, 54(6): 638-643. doi: 10.3760/cma.j.cn112150-20190711-00558
[15]	Bulut S, Aktas BK, Erkmen AE, et al. Metabolic syndrome prevalence in renal cell cancer patients[J]. Asian Pac J Cancer Prev, 2014, 15(18): 7925-7928. doi: 10.7314/APJCP.2014.15.18.7925
[16]	徐涛. 肾癌与代谢因素相关性探讨[D]. 南京: 东南大学, 2018.
[17]	Graff RE, Sanchez A, Tobias DK, et al. Type 2 Diabetes in Relation to the Risk of Renal Cell Carcinoma Among Men and Women in Two Large Prospective Cohort Studies[J]. Diabetes Care, 2018, 41(7): 1432-1437. doi: 10.2337/dc17-2518
[18]	李明, 刘俊, 胡卫列, 等. 二甲双胍对肾癌细胞凋亡的影响及机制[J]. 南方医科大学学报, 2011, 31(9): 1504-1508. https://www.cnki.com.cn/Article/CJFDTOTAL-DYJD201109009.htm
[19]	Liu J, Li M, Song B, et al. Metformin inhibits renal cell carcinoma in vitro and in vivo xenograft[J]. Urol Oncol, 2013, 31(2): 264-270. doi: 10.1016/j.urolonc.2011.01.003
[20]	曾胜, 李伟, 刘鹏, 等. 代谢综合征与肾透明细胞癌相关性研究[J]. 中华肿瘤防治杂志, 2017, 24(6): 398-402. https://www.cnki.com.cn/Article/CJFDTOTAL-QLZL201706009.htm
[21]	Colt JS, Schwartz K, Graubard BI, et al. Hypertension and risk of renal cell carcinoma among white and black Americans[J]. Epidemiology, 2011, 22(6): 797-804. doi: 10.1097/EDE.0b013e3182300720
[22]	Colt JS, Hofmann JN, Schwartz K, et al. Antihypertensive medication use and risk of renal cell carcinoma[J]. Cancer Causes Control, 2017, 28(4): 289-297. doi: 10.1007/s10552-017-0857-3
[23]	Turco F, Tucci M, Di Stefano RF, et al. Renal cell carcinoma(RCC): fatter is better? A review on the role of obesity in RCC[J]. Endocr Relat Cancer, 2021, 28(7): R207-R216. doi: 10.1530/ERC-20-0457
[24]	Sanchez A, Furberg H, Kuo F, et al. Transcriptomic signatures related to the obesity paradox in patients with clear cell renal cell carcinoma: a cohort study[J]. Lancet Oncol, 2020, 21(2): 283-293. doi: 10.1016/S1470-2045(19)30797-1
[25]	Van Hemelrijck M, Garmo H, Hammar N, et al. The interplay between lipid profiles, glucose, BMI and risk of kidney cancer in the Swedish AMORIS study[J]. Int J Cancer, 2012, 130(9): 2118-2128. doi: 10.1002/ijc.26212
[26]	Horiguchi A, Ito K, Sumitomo M, et al. Decreased serum adiponectin levels in patients with metastatic renal cell carcinoma[J]. Jpn J Clin Oncol, 2008, 38(2): 106-111. doi: 10.1093/jjco/hym158
[27]	Kocher NJ, Rjepaj C, Robyak H, et al. Hypertension is the primary component of metabolic syndrome associated with pathologic features of kidney cancer[J]. World J Urol, 2017, 35(1): 67-72. doi: 10.1007/s00345-016-1850-2
[28]	吕建敏, 李霖, 刘溪, 等. 代谢综合征与肾癌恶性程度相关性研究[J]. 临床泌尿外科杂志, 2016, 31(12): 1088-1091. https://www.cnki.com.cn/Article/CJFDTOTAL-LCMW201612010.htm
[29]	Ozbek E, Otunctemur A, Sahin S, et al. Renal cell carcinoma is more aggressive in Turkish patients with the metabolic syndrome[J]. Asian Pac J Cancer Prev, 2013, 14(12): 7351-7354. doi: 10.7314/APJCP.2013.14.12.7351
[30]	Zhu Y, Wang HK, Zhang HL, et al. Visceral obesity and risk of high grade disease in clinical t1a renal cell carcinoma[J]. J Urol, 2013, 189(2): 447-453. doi: 10.1016/j.juro.2012.09.030
[31]	Steffens S, Grünwald V, Ringe KI, et al. Does obesity influence the prognosis of metastatic renal cell carcinoma in patients treated with vascular endothelial growth factor-targeted therapy?[J]. Oncologist, 2011, 16(11): 1565-1571. doi: 10.1634/theoncologist.2011-0213
[32]	权良明. 代谢综合征对肾细胞癌围手术期的影响[D]. 芜湖: 皖南医学院, 2017.
[33]	Eskelinen TJ, Kotsar A, Tammela T, et al. Components of metabolic syndrome and prognosis of renal cell cancer[J]. Scand J Urol, 2017, 51(6): 435-441. doi: 10.1080/21681805.2017.1352616
[34]	Kriegmair MC, Mandel P, Porubsky S, et al. Metabolic Syndrome Negatively Impacts the Outcome of Localized Renal Cell Carcinoma[J]. Horm Cancer, 2017, 8(2): 127-134. doi: 10.1007/s12672-017-0289-2
[35]	Liu Z, Wang H, Zhang L, et al. Metabolic syndrome is associated with improved cancer-specific survival in patients with localized clear cell renal cell carcinoma[J]. Transl Androl Urol, 2019, 8(5): 507-518. doi: 10.21037/tau.2019.10.04
[36]	Luzzago S, Palumbo C, Rosiello G, et al. Metabolic Syndrome Predicts Worse Perioperative Outcomes in Patients Treated With Partial Nephrectomy for Renal Cell Carcinoma[J]. Urology, 2020, 140: 91-97. doi: 10.1016/j.urology.2020.02.019
[37]	Chen L, Li H, Gu L, et al. The Impact of Diabetes Mellitus on Renal Cell Carcinoma Prognosis: A Meta-Analysis of Cohort Studies[J]. Medicine(Baltimore), 2015, 94(26): e1055.
[38]	Antonelli A, Arrighi N, Corti S, et al. Pre-existing type-2 diabetes is not an adverse prognostic factor in patients with renal cell carcinoma: a single-center retrospective study[J]. Urol Oncol, 2013, 31(7): 1310-1315. doi: 10.1016/j.urolonc.2011.12.013
[39]	Höfner T, Zeier M, Hatiboglu G, et al. The impact of type 2 diabetes on the outcome of localized renal cell carcinoma[J]. World J Urol, 2014, 32(6): 1537-1542. doi: 10.1007/s00345-013-1231-z
[40]	Park B, Jeong BC, Seo SI, et al. Influence of body mass index, smoking, and blood pressure on survival of patients with surgically-treated, low stage renal cell carcinoma: a 14-year retrospective cohort study[J]. J Korean Med Sci, 2013, 28(2): 227-236. doi: 10.3346/jkms.2013.28.2.227
[41]	Parker A, Freeman LB, Cantor K, et al. Self-report of smoking, obesity and hypertension history and survival among a cohort of iowa renal cell carcinoma cases[J]. Ann Epidemiol, 2000, 10(7): 467-468.
[42]	Haddad AQ, Jiang L, Cadeddu JA, et al. Statin Use and Serum Lipid Levels Are Associated With Survival Outcomes After Surgery for Renal Cell Carcinoma[J]. Urology, 2015, 86(6): 1146-1152. doi: 10.1016/j.urology.2015.09.015
[43]	Ohno Y, Nakashima J, Nakagami Y, et al. Clinical implications of preoperative serum total cholesterol in patients with clear cell renal cell carcinoma[J]. Urology, 2014, 83(1): 154-158. doi: 10.1016/j.urology.2013.08.052
[44]	Kaffenberger SD, Lin-Tsai O, Stratton KL, et al. Statin use is associated with improved survival in patients undergoing surgery for renal cell carcinoma[J]. Urol Oncol, 2015, 33(1): 21.e11-21.e17. doi: 10.1016/j.urolonc.2014.10.007
[45]	Choi Y, Park B, Jeong BC, et al. Body mass index and survival in patients with renal cell carcinoma: a clinical-based cohort and meta-analysis[J]. Int J Cancer, 2013, 132(3): 625-634. doi: 10.1002/ijc.27639
[46]	Hakimi AA, Furberg H, Zabor EC, et al. An epidemiologic and genomic investigation into the obesity paradox in renal cell carcinoma[J]. J Natl Cancer Inst, 2013, 105(24): 1862-1870. doi: 10.1093/jnci/djt310
[47]	Lee HW, Jeong BC, Seo SI, et al. Prognostic significance of visceral obesity in patients with advanced renal cell carcinoma undergoing nephrectomy[J]. Int J Urol, 2015, 22(5): 455-461. doi: 10.1111/iju.12716
[48]	李玮, 宁灿, 袁和兴. MAP肾周脂肪评分对后腹腔镜肾部分切除术围术期结局的预测价值及其与BMI的相关性分析[J]. 临床泌尿外科杂志, 2021, 36(2): 93-98. https://www.cnki.com.cn/Article/CJFDTOTAL-LCMW202102002.htm
[49]	Persky S, de Heer HD, McBride CM, et al. The role of weight, race, and health care experiences in care use among young men and women[J]. Obesity(Silver Spring), 2014, 22(4): 1194-200.
[50]	谢晶晶. 代谢综合征对肾癌根治术后肾功能的影响及代谢综合征肾脏病理改变[D]. 福州: 福建医科大学, 2019.
[51]	Labochka D, Moszczuk B, Kukwa W, et al. Mechanisms through which diabetes mellitus influences renal cell carcinoma development and treatment: A review of the literature[J]. Int J Mol Med, 2016, 38(6): 1887-1894. doi: 10.3892/ijmm.2016.2776
[52]	Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity[J]. Circulation, 2009, 120(16): 1640-1645. doi: 10.1161/CIRCULATIONAHA.109.192644
[53]	Bellastella G, Scappaticcio L, Esposito K, et al. Metabolic syndrome and cancer: "The common soil hypothesis"[J]. Diabetes Res Clin Pract, 2018, 143: 389-397. doi: 10.1016/j.diabres.2018.05.024
[54]	Uzunlulu M, Telci Caklili O, Oguz A. Association between Metabolic Syndrome and Cancer[J]. Ann Nutr Metab, 2016, 68(3): 173-179. doi: 10.1159/000443743
[55]	Simone S, Gorin Y, Velagapudi C, et al. Mechanism of oxidative DNA damage in diabetes: tuberin inactivation and downregulation of DNA repair enzyme 8-oxo-7, 8-dihydro-2'-deoxyguanosine-DNA glycosylase[J]. Diabetes, 2008, 57(10): 2626-2636. doi: 10.2337/db07-1579
[56]	Ibrahim YH, Yee D. Insulin-like growth factor-I and cancer risk[J]. Growth Horm IGF Res, 2004, 14(4): 261-269. doi: 10.1016/j.ghir.2004.01.005
[57]	Kasprzak A. Insulin-Like Growth Factor 1(IGF-1) Signaling in Glucose Metabolism in Colorectal Cancer[J]. Int J Mol Sci, 2021, 22(12): 6434. doi: 10.3390/ijms22126434
[58]	Tracz AF, Szczylik C, Porta C, et al. Insulin-like growth factor-1 signaling in renal cell carcinoma[J]. BMC Cancer, 2016, 16: 453. doi: 10.1186/s12885-016-2437-4
[59]	Sudarshan S, Karam JA, Brugarolas J, et al. Metabolism of kidney cancer: from the lab to clinical practice[J]. Eur Urol, 2013, 63(2): 244-251. doi: 10.1016/j.eururo.2012.09.054
[60]	Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma[J]. Nature, 2013, 499(7456): 43-49. doi: 10.1038/nature12222
[61]	Tong WH, Sourbier C, Kovtunovych G, et al. The glycolytic shift in fumarate-hydratase-deficient kidney cancer lowers AMPK levels, increases anabolic propensities and lowers cellular iron levels[J]. Cancer Cell, 2011, 20(3): 315-327. doi: 10.1016/j.ccr.2011.07.018
[62]	van der Mijn JC, Panka DJ, Geissler AK, et al. Novel drugs that target the metabolic reprogramming in renal cell cancer[J]. Cancer Metab, 2016, 4: 14. doi: 10.1186/s40170-016-0154-8
[63]	Matsuda M, Shimomura I. Increased oxidative stress in obesity: implications for metabolic syndrome, diabetes, hypertension, dyslipidemia, atherosclerosis, and cancer[J]. Obes Res Clin Pract, 2013, 7(5): e330-e341. doi: 10.1016/j.orcp.2013.05.004
[64]	Zhang GM, Zhu Y, Ye DW. Metabolic syndrome and renal cell carcinoma[J]. World J Surg Oncol, 2014, 12: 236. doi: 10.1186/1477-7819-12-236
[65]	Schödel J, Ratcliffe PJ. Mechanisms of hypoxia signalling: new implications for nephrology[J]. Nat Rev Nephrol, 2019, 15(10): 641-659. doi: 10.1038/s41581-019-0182-z
[66]	Micucci C, Valli D, Matacchione G, et al. Current perspectives between metabolic syndrome and cancer[J]. Oncotarget, 2016, 7(25): 38959-38972. doi: 10.18632/oncotarget.8341
[67]	Harvey AE, Lashinger LM, Hursting SD. The growing challenge of obesity and cancer: an inflammatory issue[J]. Ann N Y Acad Sci, 2011, 1229: 45-52. doi: 10.1111/j.1749-6632.2011.06096.x
[68]	Wang Y, Zhang Y. Prognostic role of interleukin-6 in renal cell carcinoma: a meta-analysis[J]. Clin Transl Oncol, 2020, 22(6): 835-843. doi: 10.1007/s12094-019-02192-x
[69]	Sugiyama M, Takahashi H, Hosono K, et al. Adiponectin inhibits colorectal cancer cell growth through the AMPK/mTOR pathway[J]. Int J Oncol, 2009, 34(2): 339-344.
[70]	Wang H, Wu J, Gu W, et al. Serum Adiponectin Level May be an Independent Predictor of Clear Cell Renal Cell Carcinoma[J]. J Cancer, 2016, 7(10): 1340-1346. doi: 10.7150/jca.14716
[71]	Li L, Gao Y, Zhang LL, et al. Concomitant activation of the JAK/STAT3 and ERK1/2 signaling is involved in leptin-mediated proliferation of renal cell carcinoma Caki-2 cells[J]. Cancer Biol Ther, 2008, 7(11): 1787-1792. doi: 10.4161/cbt.7.11.6837
[72]	Perumal K, Mun KS, Yap NY, et al. A Study on the Immunohistochemical Expressions of Leptin and Leptin Receptor in Clear Cell Renal Cell Carcinoma[J]. Biomed Res Int, 2020, 2020: 3682086.
[73]	Horiguchi A, Sumitomo M, Asakuma J, et al. Increased serum leptin levels and over expression of leptin receptors are associated with the invasion and progression of renal cell carcinoma[J]. J Urol, 2006, 176(4 Pt 1): 1631-1635.
[74]	Ciccarese C, Brunelli M, Montironi R, et al. The prospect of precision therapy for renal cell carcinoma[J]. Cancer Treat Rev, 2016, 49: 37-44. doi: 10.1016/j.ctrv.2016.07.003
[75]	Psutka SP, Boorjian SA, Lohse CM, et al. The association between metformin use and oncologic outcomes among surgically treated diabetic patients with localized renal cell carcinoma[J]. Urol Oncol, 2015, 33(2): 67.e15-e23. doi: 10.1016/j.urolonc.2014.07.008